While additional investigation is needed to understand the mechanism of FGF23 reduction in VillinCreERT2Cyp24fl/fl mice with kidney damage, these results support inhibition of intestinal CYP24A1 as an approach to mitigate secondary hyperparathyroidism and FGF23 excess in patients with CKD. This evidence concerns the gene FGF23 and chronic kidney disease.